Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Prostate Cancer

Free Subscription Articles published in Eur Radiol Retrieve available abstracts of 100 articles: HTML format

Single Articles

June 2026
1. AGROTIS G, Thimansson E, Schoots IG
   Reference standards in AI-assisted MRI readings in prostate cancer screening: primetime for benchmarking.
   Eur Radiol. 2026 Jun 3. doi: 10.1007/s00330-026-12657.
   PubMed    
   
   
   
2. POOCH EHP, Agrotis G, Cai L, Emberton M, et al
   Semi-supervised learning in prostate MRI tumor detection approaches fully supervised performance on external validation.
   Eur Radiol. 2026;36:5011-5021.
   PubMed     Abstract available
   
   
   
3. WOO S, Tong A, Becker AS, Friedman KP, et al
   Evaluating indeterminate bone lesions and lymph nodes on PSMA-PET: a multidisciplinary consensus algorithm and 1-year implementation results.
   Eur Radiol. 2026;36:5068-5081.
   PubMed     Abstract available
   
   
   
4. DURMAZ S, Wu SJ, Lee KL, Shakur A, et al
   The effects of prostate volume and PI-RADS category on optimal PSA-density thresholds for biopsy decision-making.
   Eur Radiol. 2026;36:4503-4512.
   PubMed     Abstract available
   
   
   May 2026
5. WOO S, Curti F, Vargas HA
   Is PSMA PET/CT the answer to MRI-occult prostate cancer? Yes, but with strings attached.
   Eur Radiol. 2026 May 27. doi: 10.1007/s00330-026-12664.
   PubMed    
   
   
   
6. MAKWANA R, Esengur OT, Turkbey B
   Reproducibility analysis to support prostate MRI-informed care: independent validation of risk-stratified PSA density thresholds for clinically significant prostate cancer.
   Eur Radiol. 2026 May 13. doi: 10.1007/s00330-026-12556.
   PubMed    
   
   
   
7. STEGARESCU P, Burian E, Lutz A, Perlis N, et al
   Prostate MRI learning curves: establishing training benchmarks for radiology and urology trainees.
   Eur Radiol. 2026;36:3431-3441.
   PubMed     Abstract available
   
   
   April 2026
8. WAGNER T, Emberton M, Caglic I, Priftakis D, et al
   PSMA PET: the answer to MRI-occult prostate cancer... or another mirage?
   Eur Radiol. 2026 Apr 30. doi: 10.1007/s00330-026-12596.
   PubMed     Abstract available
   
   
   
9. ABRAHAMSEN BS, Knudtsen IS, Tulipan AJ, Hernes E, et al
   Reference tissue uptake of [18F]PSMA-1007 in positron emission tomography of recurrent prostate cancer.
   Eur Radiol. 2026 Apr 23. doi: 10.1007/s00330-026-12496.
   PubMed     Abstract available
   
   
   
10. WALLSTROM J, Jaderling F, Langkilde F, Arnsrud Godtman R, et al
    Ongoing and completed clinical trials on prostate cancer screening using MRI.
    Eur Radiol. 2026 Apr 16. doi: 10.1007/s00330-026-12533.
    PubMed     Abstract available
    
    
    
11. SMITH H, Stavrinides V, Giganti F, Moore CM, et al
    Reply to the Letter to the Editor: Variation in prostate cancer growth rates in an MRI-based active surveillance cohort.
    Eur Radiol. 2026 Apr 2. doi: 10.1007/s00330-026-12492.
    PubMed    
    
    
    
12. WANG Z, Yu C
    Letter to the Editor: Variation in prostate cancer growth rates in an MRI-based active surveillance cohort.
    Eur Radiol. 2026 Apr 1. doi: 10.1007/s00330-026-12488.
    PubMed    
    
    
    March 2026
13. ANDRADE MA, Rodrigues H, Colhado CH, Godinho NJS, et al
    Artificial-intelligence models vs. radiologists in the detection of clinically significant prostate cancer on mpMRI: a meta-analysis.
    Eur Radiol. 2026 Mar 18. doi: 10.1007/s00330-026-12465.
    PubMed     Abstract available
    
    
    February 2026
14. AGROTIS G, Jaderling F, Lakhani A, Moreira ASL, et al
    ESR Essentials: MRI-based T-staging in prostate cancer-practice recommendations by the European Society of Urogenital Radiology.
    Eur Radiol. 2026 Feb 20. doi: 10.1007/s00330-026-12397.
    PubMed     Abstract available
    
    
    
15. STANZIONE A, Cuocolo R
    Less is more? Strategies for sustainable prostate cancer screening in the era of MRI.
    Eur Radiol. 2026 Feb 19. doi: 10.1007/s00330-025-12297.
    PubMed    
    
    
    
16. VAN DEN KROONENBERG DL, Postema AW, Beerlage HP, Oddens JR, et al
    Reply to the Letter to the Editor: Evaluation of an artificial intelligence model based on multiparametric transrectal ultrasound for localizing clinically significant prostate cancer by simulation of targeted biopsies.
    Eur Radiol. 2026 Feb 10. doi: 10.1007/s00330-026-12342.
    PubMed    
    
    
    
17. BARENTSZ J, Immerzeel J, van der Leest M, Cornel E, et al
    Letter to the Editor: Evaluation of an artificial intelligence model based on multiparametric transrectal ultrasound for localising clinically significant prostate cancer by simulation of targeted biopsies.
    Eur Radiol. 2026 Feb 10. doi: 10.1007/s00330-026-12339.
    PubMed    
    
    
    
18. ENGLMAN C, Adebusoye B, Cosenza M, Del Prete A, et al
    Inter- and intra-rater variability of MRI-based lesion size measurements in active surveillance for prostate cancer: a multicentre study.
    Eur Radiol. 2026 Feb 6. doi: 10.1007/s00330-025-12318.
    PubMed     Abstract available
    
    
    
19. RENARD-PENNA R
    The velocity challenge: MRI reveals highly variable prostate cancer growth rates in active surveillance.
    Eur Radiol. 2026 Feb 6. doi: 10.1007/s00330-025-12312.
    PubMed    
    
    
    January 2026
20. DELBERGHE F, Li X, van den Kroonenberg DL, Turco S, et al
    Development of a quantitative multiparametric ultrasound and deep learning classifier for the detection of prostate cancer.
    Eur Radiol. 2026 Jan 30. doi: 10.1007/s00330-026-12323.
    PubMed     Abstract available
    
    
    
21. MUGLIA VF, Verma S
    ReIMAGINE study insights: Can abbreviated bpMRI transform prostate cancer screening?
    Eur Radiol. 2026 Jan 22. doi: 10.1007/s00330-025-11957.
    PubMed    
    
    
    
22. KASS PEREL T, Sussman MS, Ghai S
    Expanding the boundaries: rethinking ablation coverage in focal therapy for prostate cancer.
    Eur Radiol. 2026 Jan 16. doi: 10.1007/s00330-025-12245.
    PubMed    
    
    
    
23. SMITH H, Stavrinides V, Giganti F, Moore CM, et al
    Variation in prostate cancer growth rates in an MRI-based active surveillance cohort.
    Eur Radiol. 2026 Jan 16. doi: 10.1007/s00330-025-12248.
    PubMed     Abstract available
    
    
    
24. BITTON RR, Vertosick E, Khandwala Y, Korol G, et al
    Optimizing prostate cancer treatment with MR-guided focused ultrasound: the role of expanded ablation-to-lesion volume ratio.
    Eur Radiol. 2026 Jan 16. doi: 10.1007/s00330-025-12217.
    PubMed     Abstract available
    
    
    
25. OZYORUK KB, Harmon SA, Yilmaz EC, Huang EP, et al
    Artificial intelligence-generated apparent diffusion coefficient (AI-ADC) maps for prostate gland assessment: a multi-reader study.
    Eur Radiol. 2026;36:288-295.
    PubMed     Abstract available
    
    
    December 2025
26. BRATT O
    Efficacy endpoints of MRI-based prostate cancer screening: an epidemiological perspective.
    Eur Radiol. 2025 Dec 23. doi: 10.1007/s00330-025-12244.
    PubMed    
    
    
    
27. LANGKILDE F, Gren M, Wallstrom J, Kuczera S, et al
    Evaluation of AI for prostate cancer detection in biparametric-MRI screening population data.
    Eur Radiol. 2025 Dec 8. doi: 10.1007/s00330-025-12198.
    PubMed     Abstract available
    
    
    November 2025
28. YAN J, Jiang N, Wu S, Ren R, et al
    MRI evaluation of obturator internus muscle: its relationship with body composition and prognostic implications in prostate cancer patients undergoing ADT.
    Eur Radiol. 2025 Nov 27. doi: 10.1007/s00330-025-12156.
    PubMed     Abstract available
    
    
    
29. FORREST AB, Kruse DE, Calio B, Ivey MC, et al
    Detection of clinically significant prostate cancer using targeted MRI-informed microultrasound biopsy.
    Eur Radiol. 2025 Nov 22. doi: 10.1007/s00330-025-12136.
    PubMed     Abstract available
    
    
    
30. BARENTSZ JO, Ahmed HU, Miszczyk M, Catalano C, et al
    ESR Bridges: early-stage prostate cancer: new developments in imaging and treatment-a multidisciplinary view.
    Eur Radiol. 2025 Nov 7. doi: 10.1007/s00330-025-12125.
    PubMed    
    
    
    
31. VAN DEN KROONENBERG DL, Delberghe F, Jager A, Postema AW, et al
    Evaluation of an artificial intelligence model based on multiparametric transrectal ultrasound for localizing clinically significant prostate cancer by simulation of targeted biopsies.
    Eur Radiol. 2025 Nov 6. doi: 10.1007/s00330-025-12114.
    PubMed     Abstract available
    
    
    
32. WOO S, Russo L, Withey SJ, Dehghanpour A, et al
    ESUR: Opportunities for PSMA-PET/CT and whole-body MRI in advanced prostate cancer.
    Eur Radiol. 2025 Nov 5. doi: 10.1007/s00330-025-12089.
    PubMed     Abstract available
    
    
    
33. CHENG Y, Shen L, Liao Q, Qin J, et al
    Multi-reader evaluation of the prostate imaging quality score system version 2 (PI-QUAL V2) and its clinical application.
    Eur Radiol. 2025;35:7027-7039.
    PubMed     Abstract available
    
    
    
34. IVEY MC, Deivasigamani S, Kotamarti S, Mottaghi M, et al
    External validation of inter-reader reliability of the Prostate Imaging after Focal Ablation (PI-FAB) scoring system following focal cryoablation and focal high-intensity focused ultrasound.
    Eur Radiol. 2025;35:7004-7012.
    PubMed     Abstract available
    
    
    October 2025
35. PONSIGLIONE A, Cimadamore A, Girometti R
    Unmasking "unconventional" prostate cancer histologies: A real diagnostic challenge?
    Eur Radiol. 2025 Oct 31. doi: 10.1007/s00330-025-12066.
    PubMed    
    
    
    
36. RATA M, Tunariu N, Jiang Y, Hughes J, et al
    Serial T(1) and T(2) measurements of metastatic bone lesions in prostate cancer patients: MR fingerprinting vs conventional MRI.
    Eur Radiol. 2025 Oct 24. doi: 10.1007/s00330-025-12071.
    PubMed     Abstract available
    
    
    
37. GIROMETTI R, Peruzzi V, Clauser P, Potsch N, et al
    Diffusion levels for quantitative assessment of the apparent diffusion coefficient value in prostate MRI: a proof-of-concept bicentric study.
    Eur Radiol. 2025;35:6171-6182.
    PubMed     Abstract available
    
    
    September 2025
38. AGROTIS G, Ursprung S, Schoots IG
    Personalised prostate MRI: tailoring contrast medium use in an era of increasing demand.
    Eur Radiol. 2025;35:5710-5713.
    PubMed     Abstract available
    
    
    
39. SYER T, Carmo B, Sanmugalingam N, Lawson B, et al
    On-table monitoring of prostate MRI could enable tailored utilisation of gadolinium contrast.
    Eur Radiol. 2025;35:5701-5709.
    PubMed     Abstract available
    
    
    August 2025
40. THORLEY N, Parry T, Giganti F, Kopcke D, et al
    Diagnostic accuracy of abbreviated biparametric MRI for prostate cancer screening: a prospective feasibility study (ReIMAGINE study).
    Eur Radiol. 2025 Aug 6. doi: 10.1007/s00330-025-11837.
    PubMed     Abstract available
    
    
    
41. NAVES AA, de Lion Gouvea G, Machado CVB, Colli LM, et al
    Reply to the Letter to the Editor: MRI-detected extranodal extension as a marker of prostate cancer aggressiveness.
    Eur Radiol. 2025 Aug 6. doi: 10.1007/s00330-025-11897.
    PubMed    
    
    
    
42. KEIVANY MR, Zare H
    Letter to the Editor: MRI-detected extranodal extension as a marker of prostate cancer aggressiveness.
    Eur Radiol. 2025 Aug 6. doi: 10.1007/s00330-025-11896.
    PubMed    
    
    
    
43. JOHNSON PM, Tong A, Ginocchio L, Del Hoyo JL, et al
    External evaluation of an open-source deep learning model for prostate cancer detection on bi-parametric MRI.
    Eur Radiol. 2025 Aug 3. doi: 10.1007/s00330-025-11865.
    PubMed     Abstract available
    
    
    July 2025
44. NAVES AA, de Lion Gouvea G, Machado CVB, Colli LM, et al
    Reply to the Letter to the Editor: Translating MRI-detected extranodal extension into clinical practice in prostate cancer-practical considerations and future directions.
    Eur Radiol. 2025 Jul 11. doi: 10.1007/s00330-025-11811.
    PubMed    
    
    
    
45. CHEN S, Fang Y, Cheng B
    Letter to the Editor: Translating MRI-detected extranodal extension into clinical practice in prostate cancer: practical considerations and future directions.
    Eur Radiol. 2025 Jul 11. doi: 10.1007/s00330-025-11810.
    PubMed    
    
    
    
46. WOO S, Becker AS, Leithner D, Mayerhoefer ME, et al
    Discordance between prostate MRI and PSMA-PET/CT: the next big challenge for primary prostate tumor assessment?
    Eur Radiol. 2025;35:4043-4054.
    PubMed     Abstract available
    
    
    June 2025
47. FRANSEN SJ, Bosma JS, van Lohuizen Q, Roest C, et al
    Simulating workload reduction with an AI-based prostate cancer detection pathway using a prediction uncertainty metric.
    Eur Radiol. 2025 Jun 7. doi: 10.1007/s00330-025-11727.
    PubMed     Abstract available
    
    
    
48. LEE KL, Caglic I, Liao PH, Kessler DA, et al
    PI-QUAL version 2 image quality categorisation and inter-reader agreement compared to version 1.
    Eur Radiol. 2025;35:3096-3104.
    PubMed     Abstract available
    
    
    April 2025
49. CARLETTI F, Maggi M, Fazekas T, Rajwa P, et al
    Diagnostic accuracy of multiparametric MRI for detecting unconventional prostate cancer histology: a systematic review and meta-analysis.
    Eur Radiol. 2025 Apr 30. doi: 10.1007/s00330-025-11603.
    PubMed     Abstract available
    
    
    
50. AGROTIS G, Pooch EP, Marsitopoulos K, Vlychou M, et al
    Detection rates for prostate cancer using PI-RADS 2.1 upgrading rules in transition zone lesions align with risk assessment categories: a systematic review and meta-analysis.
    Eur Radiol. 2025 Apr 27. doi: 10.1007/s00330-025-11618.
    PubMed     Abstract available
    
    
    
51. AZMA YN, Boci N, Abramowicz K, Russo L, et al
    Influence of imaging method on fat fraction estimation for assessing bone marrow in metastatic prostate cancer.
    Eur Radiol. 2025 Apr 11. doi: 10.1007/s00330-025-11564.
    PubMed     Abstract available
    
    
    
52. NAVES AA, Gouvea GL, Machado CVB, Colli LM, et al
    MRI-detected extranodal extension as a marker of prostate cancer aggressiveness.
    Eur Radiol. 2025 Apr 5. doi: 10.1007/s00330-025-11532.
    PubMed     Abstract available
    
    
    
53. MAFFEI D, Moore CM
    Personalized risk-adapted models in prostate cancer during active surveillance using MRI-a narrative review.
    Eur Radiol. 2025 Apr 4. doi: 10.1007/s00330-025-11518.
    PubMed     Abstract available
    
    
    
54. CAMPBELL RA, Wood A, Schwen Z, Ward R, et al
    MRI and active surveillance: thoughts from across the pond.
    Eur Radiol. 2025;35:2157-2169.
    PubMed     Abstract available
    
    
    March 2025
55. EVANGELISTA L, Vallone C, Guglielmo P
    Optimizing prostate cancer diagnosis: combining imaging modalities for tailored treatment.
    Eur Radiol. 2025 Mar 25. doi: 10.1007/s00330-025-11551.
    PubMed    
    
    
    
56. WOO S, Becker AS, Leithner D, Charbel C, et al
    PSMA-avid rib lesions in prostate cancer patients: differentiating false positives from metastatic disease.
    Eur Radiol. 2025 Mar 20. doi: 10.1007/s00330-025-11514.
    PubMed     Abstract available
    
    
    
57. PADHANI AR, Papanikolaou N
    AI and human interactions in prostate cancer diagnosis using MRI.
    Eur Radiol. 2025 Mar 7. doi: 10.1007/s00330-025-11498.
    PubMed     Abstract available
    
    
    February 2025
58. GIGANTI F, Moreira da Silva N, Yeung M, Davies L, et al
    AI-powered prostate cancer detection: a multi-centre, multi-scanner validation study.
    Eur Radiol. 2025 Feb 28. doi: 10.1007/s00330-024-11323.
    PubMed     Abstract available
    
    
    
59. HAIDER MA
    PI-CAI: a landmark AI study for prostate cancer detection on MRI.
    Eur Radiol. 2025 Feb 17. doi: 10.1007/s00330-025-11454.
    PubMed    
    
    
    January 2025
60. PANEBIANCO V, Catalano C, Sanguedolce F, De Santis M, et al
    ESR Bridges: next-generation imaging in prostate cancer-a multidisciplinary view.
    Eur Radiol. 2025 Jan 31. doi: 10.1007/s00330-025-11354.
    PubMed    
    
    
    
61. KLEIBURG F, de Geus-Oei LF, Spijkerman R, Noortman WA, et al
    Baseline PSMA PET/CT parameters predict overall survival and treatment response in metastatic castration-resistant prostate cancer patients.
    Eur Radiol. 2025 Jan 22. doi: 10.1007/s00330-025-11360.
    PubMed     Abstract available
    
    
    December 2024
62. CAVALLO AU, Stanzione A, Ponsiglione A, Trotta R, et al
    Prostate cancer MRI methodological radiomics score: a EuSoMII radiomics auditing group initiative.
    Eur Radiol. 2024 Dec 30. doi: 10.1007/s00330-024-11299.
    PubMed     Abstract available
    
    
    
63. DEBS N, Routier A, Bone A, Rohe MM, et al
    Evaluation of a deep learning prostate cancer detection system on biparametric MRI against radiological reading.
    Eur Radiol. 2024 Dec 19. doi: 10.1007/s00330-024-11287.
    PubMed     Abstract available
    
    
    
64. BAUCKNEHT M, Laudicella R, Lanfranchi F, Ciccarese C, et al
    PSMA PET/CT in staging recurrent prostate cancer: a viewfinder, not a compass.
    Eur Radiol. 2024 Dec 18. doi: 10.1007/s00330-024-11297.
    PubMed    
    
    
    
65. BAUCKNEHT M, Laudicella R, Lanfranchi F, Burger IA, et al
    Unspecific bone uptakes in PSMA PET for prostate cancer: why do they matter?
    Eur Radiol. 2024 Dec 4. doi: 10.1007/s00330-024-11252.
    PubMed    
    
    
    
66. DIAS AB, Woo S, Leni R, Rajwa P, et al
    Is MRI ready to replace biopsy during active surveillance?
    Eur Radiol. 2024;34:7716-7727.
    PubMed     Abstract available
    
    
    
67. BOZGO V, Roest C, van Oort I, Yakar D, et al
    Prostate MRI and artificial intelligence during active surveillance: should we jump on the bandwagon?
    Eur Radiol. 2024;34:7698-7704.
    PubMed     Abstract available
    
    
    November 2024
68. RATA M, Orton MR, Tunariu N, Curcean A, et al
    Repeatability of quantitative MR fingerprinting for T(1) and T(2) measurements of metastatic bone in prostate cancer patients.
    Eur Radiol. 2024 Nov 6. doi: 10.1007/s00330-024-11162.
    PubMed     Abstract available
    
    
    
69. DE ROOIJ M, Allen C, Twilt JJ, Thijssen LCP, et al
    PI-QUAL version 2: an update of a standardised scoring system for the assessment of image quality of prostate MRI.
    Eur Radiol. 2024;34:7068-7079.
    PubMed     Abstract available
    
    
    
70. PONSIGLIONE A, Brembilla G, Cuocolo R, Gutierrez P, et al
    ESR Essentials: using the right scoring system in prostate MRI-practice recommendations by ESUR.
    Eur Radiol. 2024;34:7481-7491.
    PubMed     Abstract available
    
    
    
71. VAN LOHUIZEN Q, Roest C, Simonis FFJ, Fransen SJ, et al
    Assessing deep learning reconstruction for faster prostate MRI: visual vs. diagnostic performance metrics.
    Eur Radiol. 2024;34:7364-7372.
    PubMed     Abstract available
    
    
    October 2024
72. HAMM CA, Baumgartner GL, Padhani AR, Frobose KP, et al
    Reduction of false positives using zone-specific prostate-specific antigen density for prostate MRI-based biopsy decision strategies.
    Eur Radiol. 2024;34:6229-6240.
    PubMed     Abstract available
    
    
    
73. MARVASO G, Isaksson LJ, Zaffaroni M, Vincini MG, et al
    Can we predict pathology without surgery? Weighing the added value of multiparametric MRI and whole prostate radiomics in integrative machine learning models.
    Eur Radiol. 2024;34:6241-6253.
    PubMed     Abstract available
    
    
    September 2024
74. BOSCHHEIDGEN M, Schimmoller L, Radtke JP, Kastl R, et al
    MRI characteristics predict risk of pathological upgrade in patients with ISUP grade group 1 prostate cancer.
    Eur Radiol. 2024 Sep 13. doi: 10.1007/s00330-024-11062.
    PubMed     Abstract available
    
    
    August 2024
75. FRANSEN SJ, Kwee TC, Rouw D, Roest C, et al
    Patient perspectives on the use of artificial intelligence in prostate cancer diagnosis on MRI.
    Eur Radiol. 2024 Aug 14. doi: 10.1007/s00330-024-11012.
    PubMed     Abstract available
    
    
    
76. ISRAEL B
    From data to decisions: deep learning is shaping prostate cancer diagnostics.
    Eur Radiol. 2024 Aug 2. doi: 10.1007/s00330-024-10997.
    PubMed    
    
    
    July 2024
77. AGROTIS G, Pooch E, Abdelatty M, Benson S, et al
    Diagnostic performance of ADC and ADCratio in MRI-based prostate cancer assessment: A systematic review and meta-analysis.
    Eur Radiol. 2024 Jul 12. doi: 10.1007/s00330-024-10890.
    PubMed     Abstract available
    
    
    
78. SCHRADER A, Netzer N, Hielscher T, Gortz M, et al
    Prostate cancer risk assessment and avoidance of prostate biopsies using fully automatic deep learning in prostate MRI: comparison to PI-RADS and integration with clinical data in nomograms.
    Eur Radiol. 2024 Jul 2. doi: 10.1007/s00330-024-10818.
    PubMed     Abstract available
    
    
    
79. STANZIONE A, Lee KL, Sanmugalingam N, Rajendran I, et al
    Expect the unexpected: investigating discordant prostate MRI and biopsy results.
    Eur Radiol. 2024;34:4810-4820.
    PubMed     Abstract available
    
    
    
80. LANGKILDE F, Masaba P, Edenbrandt L, Gren M, et al
    Manual prostate MRI segmentation by readers with different experience: a study of the learning progress.
    Eur Radiol. 2024;34:4801-4809.
    PubMed     Abstract available
    
    
    June 2024
81. PADHANI AR, Tunariu N, Perez-Lopez R, Tombal B, et al
    Evaluating prostate cancer bone metastases response with whole-body MRI: What we know and still need to know.
    Eur Radiol. 2024 Jun 20. doi: 10.1007/s00330-024-10864.
    PubMed    
    
    
    
82. NAKAI H, Suman G, Adamo DA, Navin PJ, et al
    Natural language processing pipeline to extract prostate cancer-related information from clinical notes.
    Eur Radiol. 2024 Jun 6. doi: 10.1007/s00330-024-10812.
    PubMed     Abstract available
    
    
    
83. PONSIGLIONE A, Gambardella M, Stanzione A, Green R, et al
    Radiomics for the identification of extraprostatic extension with prostate MRI: a systematic review and meta-analysis.
    Eur Radiol. 2024;34:3981-3991.
    PubMed     Abstract available
    
    
    May 2024
84. OERTHER B, Engel H, Nedelcu A, Strecker R, et al
    Performance of an ultra-fast deep-learning accelerated MRI screening protocol for prostate cancer compared to a standard multiparametric protocol.
    Eur Radiol. 2024 May 23. doi: 10.1007/s00330-024-10776.
    PubMed     Abstract available
    
    
    
85. BREMBILLA G, Giganti F
    Improving image quality in prostate MRI: the time is now.
    Eur Radiol. 2024;34:3385-3386.
    PubMed    
    
    
    
86. NAKAI H, Takahashi H, Adamo DA, LeGout JD, et al
    Decreased prostate MRI cancer detection rate due to moderate to severe susceptibility artifacts from hip prosthesis.
    Eur Radiol. 2024;34:3387-3399.
    PubMed     Abstract available
    
    
    April 2024
87. MUGLIA VF
    Refining clinical decision strategies and prostate cancer detection through fine adjustments in the combination of PSA-derived parameters and MRI.
    Eur Radiol. 2024 Apr 29. doi: 10.1007/s00330-024-10734.
    PubMed    
    
    
    
88. CAGLIC I, Sushentsev N, Syer T, Lee KL, et al
    Biparametric MRI in prostate cancer during active surveillance: is it safe?
    Eur Radiol. 2024 Apr 24. doi: 10.1007/s00330-024-10770.
    PubMed     Abstract available
    
    
    
89. BOELLAARD TN, van Dijk-de Haan MC, Heijmink SWTPJ, Tillier CN, et al
    Membranous urethral length measurement on preoperative MRI to predict incontinence after radical prostatectomy: a literature review towards a proposal for measurement standardization.
    Eur Radiol. 2024;34:2621-2640.
    PubMed     Abstract available
    
    
    March 2024
90. GIROMETTI R, Giganti F
    Active surveillance of prostate cancer: MRI and beyond.
    Eur Radiol. 2024 Mar 28. doi: 10.1007/s00330-024-10717.
    PubMed    
    
    
    February 2024
91. PADHANI AR, Godtman RA, Schoots IG
    Key learning on the promise and limitations of MRI in prostate cancer screening.
    Eur Radiol. 2024 Feb 5. doi: 10.1007/s00330-024-10626.
    PubMed     Abstract available
    
    
    January 2024
92. MAZZETTI S, Defeudis A, Nicoletti G, Chiorino G, et al
    Development and validation of a clinical decision support system based on PSA, microRNAs, and MRI for the detection of prostate cancer.
    Eur Radiol. 2024 Jan 4. doi: 10.1007/s00330-023-10542.
    PubMed     Abstract available
    
    
    
93. PANEBIANCO V
    Prostate cancer imaging for primary detection: PSMA-PET/CT vs MRI. All that glitters is not gold.
    Eur Radiol. 2024 Jan 2. doi: 10.1007/s00330-023-10547.
    PubMed    
    
    
    December 2023
94. EVANGELISTA L, Filippi L
    Structured reporting in prostate cancer: the revolution of quality in nuclear medicine scan interpretation.
    Eur Radiol. 2023 Dec 20. doi: 10.1007/s00330-023-10507.
    PubMed    
    
    
    
95. NOTO B, Eveslage M, Auf der Springe K, Exler A, et al
    Robustness of apparent diffusion coefficient-based lymph node classification for diagnosis of prostate cancer metastasis.
    Eur Radiol. 2023 Dec 15. doi: 10.1007/s00330-023-10406.
    PubMed     Abstract available
    
    
    
96. JANNUSCH K, Bruckmann NM, Morawitz J, Boschheidgen M, et al
    Recurrent prostate cancer: combined role for MRI and PSMA-PET in (68)Ga-PSMA-11 PET/MRI.
    Eur Radiol. 2023 Dec 1. doi: 10.1007/s00330-023-10442.
    PubMed     Abstract available
    
    
    
97. ROUVIERE O
    Contrast-medium administration for prostate MRI can be abandoned: no(t so simple)!
    Eur Radiol. 2023;33:8415-8416.
    PubMed    
    
    
    
98. ASBACH P
    Contrast-medium administration for prostate MRI: yes! Contrast-medium administration can be abandoned.
    Eur Radiol. 2023;33:8413-8414.
    PubMed    
    
    
    November 2023
99. MA J, Yang Q, Ye X, Xu W, et al
    Head-to-head comparison of prostate-specific membrane antigen PET and multiparametric MRI in the diagnosis of pretreatment patients with prostate cancer: a meta-analysis.
    Eur Radiol. 2023 Nov 20. doi: 10.1007/s00330-023-10436.
    PubMed     Abstract available
    
    
    
100. NETZER N, Eith C, Bethge O, Hielscher T, et al
     Application of a validated prostate MRI deep learning system to independent same-vendor multi-institutional data: demonstration of transferability.
     Eur Radiol. 2023;33:7463-7476.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum